What is the ICD-10 (International Classification of Diseases, 10th Revision) code for a patient with a BI-RADS (Breast Imaging-Reporting and Data System) 4 classification?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ICD-10 Code for BI-RADS 4

The ICD-10 code for a BI-RADS 4 finding is typically R92.0 (mammographic microcalcification found on diagnostic imaging of breast) or R92.8 (other abnormal and inconclusive findings on diagnostic imaging of breast), depending on the specific imaging finding that prompted the BI-RADS 4 classification.

Understanding BI-RADS 4 Classification

BI-RADS Category 4 designates findings that are suspicious and warrant biopsy, with a malignancy risk ranging from greater than 2% to less than 95% 1. This category covers a wide spectrum of suspicion and does not fulfill typical criteria for malignancy but raises enough concern to recommend tissue diagnosis 2.

Appropriate ICD-10 Coding Based on Imaging Findings

The specific ICD-10 code depends on what imaging abnormality triggered the BI-RADS 4 assessment:

For Microcalcifications

  • R92.0 - Mammographic microcalcification found on diagnostic imaging of breast 1
  • This is appropriate when suspicious calcifications are the primary finding prompting BI-RADS 4 classification 3

For Masses or Other Findings

  • R92.8 - Other abnormal and inconclusive findings on diagnostic imaging of breast 1
  • Use this code for suspicious masses, architectural distortion, or other non-calcification findings 4

For Dense Breast Tissue (if relevant)

  • R92.2 - Inconclusive mammogram due to dense breasts 5
  • This may be used as a secondary code if breast density is a contributing factor

Clinical Management Context

BI-RADS 4 lesions require tissue diagnosis using core needle biopsy (preferred) or needle localization excisional biopsy with specimen radiograph 6. The positive predictive value for malignancy in BI-RADS 4 lesions ranges from 34% to 44.9%, meaning more than half are ultimately benign 7, 8.

Important Coding Considerations

  • The ICD-10 code reflects the imaging finding, not the BI-RADS category itself 1
  • If biopsy confirms malignancy, the code changes to the specific breast cancer diagnosis (C50.x series) 6
  • If biopsy shows benign pathology with imaging concordance, follow-up codes would reflect benign breast conditions 6

Common Pitfalls to Avoid

  • Do not use cancer diagnosis codes (C50.x) before histopathologic confirmation, even for BI-RADS 4 or 5 lesions 6
  • Ensure pathology-imaging concordance is documented; discordant results require additional tissue sampling and may affect coding 1
  • BI-RADS 4 can be subcategorized (4A, 4B, 4C) with increasing malignancy risk (10%, 21%, and 70% respectively), but this does not change the ICD-10 code 3

References

Guideline

BIRADS Classification and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

MRI in the Assessment of BI-RADS® 4 lesions.

Topics in magnetic resonance imaging : TMRI, 2017

Research

A New Practical Decision Rule to Better Differentiate BI-RADS 3 or 4 Breast Masses on Breast Ultrasound.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2022

Guideline

Ultrasound for BI-RADS 1 with Dense Breasts

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.